| Name | Title | Contact Details |
|---|---|---|
Masashi Shimazaki |
VP, Head of CI & Research Program Management in Oncology Research | Profile |
Wayne Berryman |
Assistant Director Information Security | Profile |
Anand Pattabiraman |
Senior Director of Information Systems | Profile |
Since 1989 Robinson Pharma, Inc. (RPI) has served domestic and international marketers of vitamins and dietary supplements. From its humble beginnings as a contract packager, RPI has grown to become a significant entity in the dietary supplement industry
Specialty Therapeutic Care is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
AcariaHealth is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Intendis Inc is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.